Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
暂无分享,去创建一个
M. Triggiani | W. Aberer | M. Gompels | H. Farkas | M. Cicardi | E. Aygören‐Pürsün | C. Katelaris | M. Maurer | W. Sheridan | W. Rae | H. Longhurst | M. Magerl | O. Fain | M. Baeza | A. Huissoon | M. Guilarte | J. Greve | T. Kinaciyan | A. Zanichelli | L. Fang | A. Bygum | J. Graff | T. González-Quevedo | A. Du-Thanh | William B Smith | R. Lleonart | U. Steiner | V. Grivcheva-Panovska | M. Cornpropst | S. Dobo | M. Cancian | D. Clemons | P. Collis
[1] M. Triggiani,et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study , 2018, Allergy.
[2] C. Wahlgren,et al. Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden. , 2017, Allergy and asthma proceedings.
[3] William H. Yang,et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.
[4] B. Zuraw,et al. Tolerability and Effectiveness of 17-α-Alkylated Androgen Therapy for Hereditary Angioedema: A Re-examination. , 2016, The journal of allergy and clinical immunology. In practice.
[5] P. Martus,et al. The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important difference , 2016, Allergy. European Journal of Allergy and Clinical Immunology.
[6] W. Sheridan,et al. BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition When Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects , 2016 .
[7] P. Martus,et al. Development, validation, and initial results of the Angioedema Activity Score , 2013, Allergy.
[8] P. Martus,et al. Development and construct validation of the angioedema quality of life questionnaire , 2012, Allergy.
[9] K. Bork,et al. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.
[10] M. Cicardi,et al. Hereditary angio-oedema , 2012, The Lancet.
[11] K. Bork,et al. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[12] K. Kragballe,et al. Hereditary Angioedema. , 2018, The New England journal of medicine.
[13] S. Choquet,et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. , 2000, The Journal of allergy and clinical immunology.
[14] M. Cicardi,et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. , 1997, The Journal of allergy and clinical immunology.
[15] J. Beechem,et al. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. , 1991, Biochemistry.